

# Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Committee

## Summary of Main Points from the Meeting held on Monday 13<sup>th</sup> April 2015

### 2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the March 2015 meeting were approved and will be circulated.

### 3. Matters Arising

The Committee noted the matters arising from the previous meeting.

### 4. Formulary Applications

#### **Full applications**

No full applications

#### **Individual funding requests (For noting)**

- **Infliximab**

#### **Decision: Noted**

Previously approved by the Pharmacoeconomics Board for the management of a specific patient with refractory ocular sarcoidosis. Funding has been approved by NWL CCG.

- **Eltrombopag**

#### **Decision: Noted**

Previously approved by the Pharmacoeconomics Board for the management of a specific patient with intractable autoimmune thrombocytopenia. Funding has been approved by NHSE.

#### **Ex-Panel Requests**

#### **Decision: Approved**

- Acamprosate Calcium 333mg Enteric Coated Tablets
- Alfuzosin 10mg Modified Release Tablets
- Amorolfine 5% Paint
- Anastrozole 1mg Tablets
- Apraclonidine 0.5 % Eye Drops
- Bifidobacterium (Baby Infantis) 4 Billion Viable Cells Powder
- Celecoxib 100 mg Capsules
- Celecoxib 200 mg Capsules
- Dalteparin 10000 units in 0.4ml pre-filled syringe
- Dalteparin 12,500 units in 0.5 ml Syringe
- Dalteparin 5000i.u. Syringe
- Dalteparin graduated syringe 10,000iu in 1 ml Syringe
- Dornase Alfa (Pulmozyme) 2500 units in 2.5ml (2.5mg) Nebuliser Solution
- Doxycycline 100 mg Dispersible Tablet
- Etoricoxib 60 mg Tablets
- Etoricoxib 90 mg Tablets
- Glycopyrronium Bromide 1 mg in 1ml Oral Solution
- Hydrocortisone 0.1 % Cream
- Lamotrigine (Lamictal) 100 mg Dispersible Chewable Tablet
- Lamotrigine (Lamictal) 100 mg Tablets
- Lamotrigine (Lamictal) 25 mg Dispersible Chewable Tablet
- Levetiracetam (Keppra) 250 mg Tablets
- Levetiracetam (Keppra) 100 mg in 1ml Oral Liquid
- Levetiracetam (Keppra) 500 mg Tablets
- Levothyroxine 100 micrograms/5ml Oral Liquid
- Logynon Tablets
- Melatonin (Circadin) MR 2 mg Tablets
- Mesalazine (Pentasa) 1 g Prolonged Release Granules
- Methylidopa 250 mg Tablets
- Ondansetron 16mg Suppositories
- Perampanel 2mg Tablets
- Perampanel 4mg Tablets
- Perampanel 6 mg Tablets
- Pramipexole (Base) 88micrograms Tablets
- Pramipexole MR (Base) 1.05mg Tablets
- Pramipexole MR (Base) 2.1mg Tablets
- Pramipexole MR (Base) 260micrograms Tablets
- Prednisolone 25mg Tablets
- Ropinirole 250micrograms Tablets

**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Committee**

- Rotigotine 2mg/24 hours Patch
- Rotigotine 4mg in 24 hours Patch
- Sunscreen (Uvistat) SPF50 Cream
- Tocilizumab 200mg in 10 ml Injection
- Tocilizumab 400mg in 20ml Injection
- Tocilizumab 80mg in 4ml Injection
- Topiramate (Topamax) 25mg Tablets
- Valganciclovir 450mg Tablets
- Zoledronic acid 4 mg Injection

**5. Trust Medicines Policy**

- **Appendix: 5. Process for Demand Management of IVIg**

**Decision: Noted**

Updates to policy to reflect the change in the IVIg designated person.

- **Antiretroviral Policy**

**Decision: Noted**

Policy for antiretroviral prescribing and monitoring within the HIV/GUM directorate.

**6. Medicines Management**

- **Trust Non Medical Prescribing Lead**

**Decision: Noted**

Appointment of Trust Non Medical prescribing lead: Claire Wilson and David Taylor (Shared)

- **Trust PGD Lead**

**Decision: Noted**

Appointment of Trust PGD lead: Pippa Scott

- **Change in Albumin Supply Memo**

**Decision: Noted**

Trustwide memo circulated in light of changes to the supply of albumin

**7. NICE TA Guidance**

- TA335 – Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

**Action: Currently included in formulary. To update formulary to indicate that rivaroxaban is to be used in line with NICE TA335**

- TA336 – Empagliflozin in combination therapy for treating type 2 diabetes

**Action: Add to formulary pending full application from endocrinologist**

- TA337 – Rifaximin for preventing episodes of overt hepatic encephalopathy

**Action: Currently included in formulary. To update formulary to indicate that rifaximin is to be used in line with NICE TA337**

- TA338 – Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib

**Action: Nil – not recommended. To update formulary to indicate that pomalidomide is to be used in line with NICE TA335**

**8. IVIG Update**

**Decision: Noted**

- **IVIG requests**

There were 11 IVIG issues in March 2015, with 4 new requests:

- One for Severe/Recurrent C diff (blue indication)
- One for Haemophagocytic syndrome (blue indication)
- One for Kawasaki's disease (red indication)
- One for Myasthenia Gravis (blue indication)

**9. Items for noting**

- **Medicines Committee Terms of Reference**

**Decision: Noted**

Updated Terms of Reference for the Medicines Committee.

- **Audit report on medicines reconciliation on admission**

**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Committee**

**Decision: Noted**

Audit to determine if reconciliation of patients' medicines on admission meets the standard outlined in the Trust Medicines Policy.

- **MHRA Update**
  - **March 2015**

**Decision: Noted**

MHRA update for March 2015

**Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia**

**Action: To disseminate to Neurology Team.**

- **Cancer Drugs Fund List**

**Decision: Noted**

List of drugs approved by the National Cancer Drugs Fund for specified indications as of 12/03/2015.

- **NWLIF compliance audit Q4 2014/2015**

**Decision: Noted**

Audit of prescribing compliance with the NWLIF Q4 2014/2015

**10. Meeting minutes for noting**

- **HIV Drugs Sub-committee meeting – January 2015**

**Decision: Noted**

**13. Date of next meeting**

**Monday 11th May: 8.00 - 9.00**

**Board Room: Lower Ground Floor, Lift Bank B**

**Closing date for papers: Friday 17<sup>th</sup> April 2015**